These recommendations provides a much‐needed framework for clinicians performing and interpreting tests of anorectal function.
There has been an increase in the incidence of squamous cell carcinoma of the anus (SCCA) in the United States.
Stool banks may guarantee reliable, timely and equitable access to fecal microbiota transplantation for patients and a traceable workflow that ensures safety and quality of procedures.
Discontinuation of anti–TNF therapy in patients with perianal Crohn disease may increase the risk for fistula relapse.
In patients with chronic constipation, the most common form of anorectal dysfunction is Type 1 dyssynergic defecation.
This study provides normative values for the bilateral lumbar and sacral-anorectal MEPs in healthy subject with no age or gender influence on rectal or anal MEP latency.
An interdisciplinary group treatment for fecal incontinence in children (called “Poop group” by investigators) is a promising alternative for up to 60% of patients who fail to respond to standard care.
Men are less knowledgeable than women about human papillomavirus (HPV), HPV vaccination, and the correlation between HPV and cancer.
This study demonstrated that a reduction in internal anal sphincter function was more common not only in patients with rectoanal intussusception, but also in those without rectocele.
MAGNIFI-CD has improved operating characteristics compared to other indices assessing MRI scans of perianal fistula activity in CD, and that the new index may be useful as an outcome measure in clinical trials investigating treatment for perianal fistulizing CD.
Study concludes that few of the associated risk factors are modifiable and that clinicians should stress possible outcomes related to urinary dysfunction prior to patients receiving treatment for rectal cancer.
Early results from the Polish II study showed a significant improvement in OS for preoperative short-course RT/chemotherapy compared with long-term chemo-RT.
Researchers conducted a double-blind study to assess the effect of naldemedine therapy vs placebo in reducing symptoms associated with opioid-induced constipation.